Fisher Asset Management LLC Has $55.40 Million Holdings in Viridian Therapeutics, Inc. $VRDN

by · The Cerbat Gem

Fisher Asset Management LLC raised its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 48.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,780,284 shares of the company’s stock after buying an additional 579,058 shares during the quarter. Fisher Asset Management LLC’s holdings in Viridian Therapeutics were worth $55,402,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd acquired a new position in Viridian Therapeutics in the fourth quarter valued at approximately $36,000. Aster Capital Management DIFC Ltd acquired a new position in Viridian Therapeutics in the third quarter valued at approximately $35,000. Bessemer Group Inc. lifted its stake in Viridian Therapeutics by 947.7% in the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock valued at $45,000 after buying an additional 1,886 shares during the period. Larson Financial Group LLC acquired a new position in Viridian Therapeutics in the third quarter valued at approximately $52,000. Finally, US Bancorp DE lifted its stake in Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after buying an additional 463 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on VRDN. Weiss Ratings reissued a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Monday, April 20th. Royal Bank Of Canada boosted their price target on Viridian Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Evercore set a $26.00 price target on Viridian Therapeutics in a research note on Friday, May 15th. The Goldman Sachs Group dropped their price target on Viridian Therapeutics from $36.00 to $31.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Finally, Wedbush lowered their target price on Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Viridian Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $36.14.

Check Out Our Latest Stock Report on VRDN

Insider Buying and Selling

In related news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the transaction, the director owned 5,090,928 shares of the company’s stock, valued at $86,545,776. This represents a 30.05% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.40% of the company’s stock.

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN opened at $17.00 on Wednesday. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. Viridian Therapeutics, Inc. has a twelve month low of $13.18 and a twelve month high of $34.29. The stock’s 50 day moving average is $18.40 and its 200-day moving average is $26.38. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -5.12 and a beta of 0.82.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.Viridian Therapeutics’s revenue for the quarter was up 95.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.87) earnings per share. Sell-side analysts forecast that Viridian Therapeutics, Inc. will post -3.71 EPS for the current fiscal year.

Viridian Therapeutics Company Profile

(Free Report)

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

Further Reading

Want to see what other hedge funds are holding VRDN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report).